The TITAN trial - Assessing the efficacy and safety of an anti-von Willebrand factor Nanobody in patients with acquired thrombotic thrombocytopenic purpura

Transfusion and Apheresis Science

Volumn 46, Issue 3, 2012, Pages 343-346

  Holz, Josefin Beate ^a  

^a ABLYNX NV   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ALX 0081; ANTIBODY; NANOPARTICLE; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR NANOBODY;

ARTICLE; DRUG EFFICACY; DRUG SAFETY; HUMAN; PLASMAPHERESIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; UNSPECIFIED SIDE EFFECT;

ADULT; ANIMALS; CAMELIDS, NEW WORLD; FEMALE; HUMANS; MALE; PLASMA EXCHANGE; PURPURA, THROMBOTIC THROMBOCYTOPENIC; SINGLE-CHAIN ANTIBODIES; VON WILLEBRAND FACTOR;

EID: 84860490555     PISSN: 14730502     EISSN: 18781683     Source Type: Journal    
DOI: 10.1016/j.transci.2012.03.027     Document Type: Article

References (22)

1. Amorosi E., Ultmann J.E. Thrombotic thrombocytopenic purpura: report of 16 cases and review of the literature. Medicine 1966, 45:139-159.
2. Moake J.L. Thrombotic microangiopathies. N Engl J Med 2002, 347(8):589-600.
3. Sadler J.E. A new name in thrombosis, ADAMTS13. PNAS 2002, 99(18):11552-11554.
4. Ruggeri Z.M. Von Willebrand factor: looking back and looking forward. Thromb Haemost 2007, 98(1):55-62.
5. Dong J.F., Moake J.L., Nolasco L., Bernardo A., Arceneaux W., Shrimpton C.N., Schade A.J., McIntire L.V., Fujikawa K., Lopez J.A. ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions. Blood 2002, 100(12):4033-4039.
6. Furlan M., Robles R., Galbusera M., Remuzzi G., Kyrle P.A., Brenner B., Krause M., Scharrer I., Aumann V., Mittler U., Solenthaler M., Lammle B. Von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 1998, 339(22):1578-1584.
7. Lammle B., Kremer Hovinga J.A., Alberio L. Thrombotic thrombocytopenic purpura. J Thromb Haemost 2005, 3(8):1663-1675.
8. Furlan M., Robles R., Solenthaler M., Wassmer M., Sandoz P., Lammle B. Deficient activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura. Blood 1997, 89(9):3097-3103.
9. Zheng X.L., Kaufman R.M., Goodnough L.T., Sadler J.E. Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura. Blood 2004, 103(11):4043-4049.
10. George J.N., Kremer Hovinga J.A., Terrell D.R., Vesely S.K., Lammle B. The oklahoma thrombotic thrombocytopenic purpura-hemolytic uremic syndrome registry: the swiss connection. Eur J Haematol 2008, 80(4):277-286.
11. Torok T.J., Holman R.C., Chorba T.L. Increasing mortality from thrombotic thrombocytopenic purpura in the United States - analysis of national mortality data, 1968-1991. Am J Hematol 1995, 50(2):84-90.
12. Rock G.A., Shumak K.H., Buskard N.A., Blanchette V.S., Kelton J.G., Nair R.C., Spasoff R.A. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N Engl J Med 1991, 325(6):393-397.
13. George J.N., How I. Treat patients with thrombotic thrombocytopenic purpura. Blood 2010, 116(20):4060-4069.
14. Ulrichts H., Silence K., Schoolmeester A., de Jaegere P., Rossenu S., Roodt J., Priem S., Lauwereys M., Casteels P., Van Bockstaele F., Verschueren K., Stanssens P., Baumeister J., Holz J.B. Antithrombotic drug candidate ALX-0081 shows superior preclinical efficacy and safety compared to currently marketed antiplatelet drugs. Blood 2011, 118(3):757-765.
15. Bartunek J., Barbato E., Holz J.-B., Vercruysse K., Ulrichts H., Heyndrickx G. ALX-0081 a novel antithrombotic: results of a single-dose Phase 1 study in healthy volunteers and further development in patients with stable angina. Circulation 2008, 118. S-656. Abstract 2009.
16. Bartunek J., Barbato E., Vercruysse K., Duby C., Wijns W., Heyndrickx G., Holz J.-B. Safety and efficacy of anti-von Willebrand factor Nanobody ALX-0081 instable angina patients undergoing percutaneous coronary intervention. Circulation 2010, 122:A15084. Abstract 15084.
17. Allford S.L., Hunt B.J., Rose P., Machin S.J. Guidelines on the diagnosis and management of the thrombotic microangiopathic haemolytic anaemias. Br J Haematol 2003, 120(4):556-573.
18. Kremer Hovinga J.A., Meyer S.C. Current management of thrombotic thrombocytopenic purpura. Curr Opin Hematol 2008, 15(5):445-450.
19. Elliott M.A., Nichols W.L., Plumhoff E.A., Ansell S.M., Dispenzieri A., Gastineau D.A., Gertz M.A., Inwards D.J., Lacy M.Q., Micallef I.N., Tefferi A., Litzow M. Posttransplantation thrombotic thrombocytopenic purpura: a single-center experience and a contemporary review. Mayo Clin Proc 2003, 78(4):421-430.
20. Sadler J.E., Moake J.L., Miyata T., George J.N. Recent advances in thrombotic thrombocytopenic purpura. Hematology Am Soc Hematol Educ Program 2004, 2004(1):407-423.
21. George J.N. Tibor Greenwalt Award. The oklahoma thrombotic thrombocytopenic purpura-hemolytic uremic syndrome registry: a program for patient care, education and research. Transfusion 2004, 44(9):1384-1392.
22. George J.N. Evaluation and management of patients with thrombotic thrombocytopenic purpura. J Intensive Care Med 2007, 22(2):82-91.